Navigation Links
SemBioSys submits IND for safflower-produced insulin to U.S. FDA
Date:7/29/2008

nformation is available and can be accessed at http://www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions and market size, the acceptance of an IND by the FDA in respect of clinical studies, the submission of a CTA to the appropriate European authorities, the successful initiation and timely and successful completion of clinical studies, the fact that Apo AI is currently a development stage drug, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.


'/>"/>
SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys updates Apo AI development program
2. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
3. SemBioSys announces 2007 third quarter results
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
6. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
7. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys initiates toxicology study for safflower-produced insulin
10. SemBioSys receives milestone payments from AVAC Ltd.
11. SemBioSys announces first quarter 2008 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Ohio (PRWEB) April 16, 2015 ... Index, overexertion involving an outside source was ranked ... This includes injuries related to lifting, pushing, pulling, ... billion in direct costs. The David Round Company ... is committed to working hard to develop and ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, ... announced its U.S. joint venture with G-treeBNT (ReGenTree ... phase 3 clinical trial for the orphan disorder, ... trial for dry eye syndrome (DES) in the ... eye drops, RGN-259/GBT201, this year.  Each of these ...
(Date:4/16/2015)... , April 16, 2015  Scientists from Cleave Biosciences ... on the Horizon," at the American Association for Cancer ... on Sunday, April 19, 2015 from 3:15pm ... Director of Biology, will present new in vivo and ... oral inhibitor of p97, a critical enzyme that controls ...
(Date:4/16/2015)... Fairleigh Dickinson University ( FDU ) ... the Executive Director of the Rothman Institute of ... of the Initiative for Patient Centered Innovation (iPCI), ... the Rothman Institute of Innovation and Entrepreneurship (within ... with FDU’s School of Pharmacy’s Center for Healthcare ...
Breaking Biology Technology:The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... the following Webcast:, What: Neurocrine Biosciences 3rd ... @ 5 p.m. Eastern 2 p.m. Pacific, Where: ... Internet -- Simply log on to the web at the address ... Claudia Woodworth, 858-617-7759 If you are unable to participate during the ...
... demand for health ... economics and market access support, BOSTON, Oct. 28 ... as Vice President., Mr. Barak brings 16 years of ... reimbursement strategies,for drugs, medical devices, and diagnostics in a wide ...
... Company Also Announces Completion of Enrollment in U.S. ... Chronic Hepatitis C,Genotype 1, TAMPA, Fla., Oct. ... today announced the presentation of studies,of nitazoxanide at ... for the Study of Liver Diseases (AASLD), also ...
Cached Biology Technology:Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability 2Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco 2
(Date:4/13/2015)... 13, 2015  higi, a leading cloud-based consumer engagement ... fully engage with their communities around health and wellness, ... and secure API.  ... accessible, affordable, and convenient vehicle to receive validated health ... The API will allow higi,s trusted partners, ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... in collaboration with scientists at the University of California, San ... protein switch that plays a crucial role in the development ... 8 issue of the journal Molecular Cell, provide a template ... switch, a protein called Scp1, at will. , "Scp1 is ...
... the plague and some forms of food poisoning "paralyze" the ... to a new study in the September 8, 2006 issue ... researchers found that these bacteria, which belong to the genus ... enzyme. That copycat protein blocks host cells' capacity to change ...
... in the open access journal PLoS Biology, Sagiv Shifman, Jonathan ... the mouse genome--one of the most detailed genetic maps now ... this map, they used two groups of mice: one consisting ... inbred lines (RI). Using the single nucleotide polymorphism (SNP) data ...
Cached Biology News:Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 2Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 3Study illuminates how the plague bacteria causes disease 2Study illuminates how the plague bacteria causes disease 3Mapping the mouse genome 2
Topoisomerase II...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... General description: Dish uses include large-scale ... Compatible with PBA Flexys TM automated ... number is a new product number, created ... showing no availability yet, please order under ...
BD BioCoat Collagen IV 150 mm Culture Dishes...
Biology Products: